Amgen exceeds Wall Street expectations with a 9% increase in product sales, driven by revenue of $9.2 billion and adjusted earnings per share of $6.02 in the second quarter. Shares dip slightly in extended trading, while sales of Repatha rise 31% and Prolia sales fall 4%.

The biotech company anticipates data in the fourth quarter from key mid-stage studies on experimental weight-loss drug MariTide, which activates receptors for appetite- and blood sugar-reducing hormone GLP-1. Amgen slightly raises its full-year financial outlook to adjusted earnings per share of $20.20 to $21.30 on revenue of $35 billion to $36 billion.

Amgen CEO Robert Bradway confirms the company’s commitment to working with the U.S. administration on healthcare reform amid pressure to lower prescription drug prices and potential tariffs on imports. Analysts estimate 2025 earnings of $20.91 per share on revenue of $35.4 billion, as Amgen continues to navigate industry challenges and opportunities.

Read more at Yahoo Finance: Amgen profit rises, weight-loss data expected in 4th quarter